Core Viewpoint - Shanghai Shengsheng has submitted its listing application to the Hong Kong Stock Exchange, with CICC and Guojin Securities (Hong Kong) as joint sponsors. The company specializes in integrated temperature-controlled supply chain services for the pharmaceutical and life sciences industry, covering preclinical research, clinical trials, and post-market commercialization [1] Company Summary - Shanghai Shengsheng is the leading provider of temperature-controlled supply chain services in the pharmaceutical and life sciences sector in China, ranked first by revenue for 2024 according to Frost & Sullivan [1] - The company is the only Chinese enterprise among the top ten global providers of clinical trial temperature-controlled supply chain services, ranked ninth globally with a market share of 1.5% for 2024 [1] - The services offered by the company include project management, clinical packaging and labeling, temperature-controlled packaging, logistics and storage, drug recovery and destruction, bonded warehousing, import and export agency, customs clearance, direct delivery to patients, and biological sample management [1] - As of January 5, 2026, the company has served over 7,000 clients and operates clinical drug warehouses and biological sample banks in Shanghai, Beijing, and Guangzhou, with more than 130 operational sites providing efficient delivery services [1] Industry Summary - The global market for temperature-controlled supply chain services for commercial medical products is projected to grow from RMB 127.1 billion in 2020 to RMB 174.8 billion in 2024, with a compound annual growth rate (CAGR) of 8.3% [2] - The Chinese market is expected to grow from RMB 16.8 billion to RMB 22.9 billion during the same period, with projections to expand to RMB 38.6 billion by 2030 [2] - The share of cold chain categories in the commercial pharmaceuticals and medical products market in China continues to increase, driving demand for compliant cold chain distribution, professional storage, and integrated distribution services [2]

Core Insights - China National Pharmaceutical Group reported a revenue of 8.819 billion yuan for Q3 2025, marking a 3.67% year-on-year increase, with a net profit of 161 million yuan, up 27.51% [1] - For the first three quarters of 2025, the total revenue reached 25.894 billion yuan, with a net profit of 455 million yuan [1] Group 1: Green Manufacturing and Low-Carbon Transition - Multiple subsidiaries of China National Pharmaceutical have achieved significant results in low-carbon production and resource recycling, creating a "green factory cluster" effect [2] - Tianshan Pharmaceutical emphasizes "green development" by promoting sustainable use of local medicinal materials and establishing GAP bases to protect regional ecosystems [2] - The company has successfully established and certified four management systems: environmental, quality, occupational health and safety, and energy, laying a solid foundation for sustainable development [2] Group 2: Rural Revitalization and Medical Services - China National Pharmaceutical has been supporting Wuchuan County in Inner Mongolia for 23 years, focusing on the revitalization of local industries, particularly the production of traditional medicinal materials [3] - The company has integrated resources with local government to enhance agricultural productivity and income for farmers through various initiatives [3] - Sanyou Pharmaceutical has been recognized as one of the top 50 manufacturing enterprises in Hainan Province for 2025, responding to national drug quality improvement policies [3] Group 3: Digital Transformation and Governance - The company is optimizing its governance system through digital transformation, enhancing core competitiveness and ensuring sustainable development [4] - A digital platform has been established for comprehensive business management, recognized as a benchmark case for digital transformation in the pharmaceutical distribution industry [4] - Key subsidiaries are focusing on technological breakthroughs in antiviral drug development and leveraging policy advantages to accelerate market penetration [4]

Core Viewpoint - The company, Sely Medical (603716.SH), anticipates a net loss attributable to shareholders of between -55 million to -66 million yuan for the first half of 2025, indicating an increase in losses compared to the same period last year [1] Group 1: Financial Performance - The expected net profit loss for the first half of 2025 is projected to be between -55 million to -66 million yuan, which represents a worsening of losses compared to the previous year [1] - The company has undergone strategic transfers of certain subsidiaries, which has had a short-term negative impact on overall revenue scale and gross profit levels [1] Group 2: Strategic Transition - The company is currently in a strategic transition phase, focusing on upgrading from traditional medical supply chain services to medical intelligence [1] - Industry policies have influenced the company's operations, leading to extended collection periods for accounts receivable from some clients [1] Group 3: Revenue and Profitability Challenges - The company has experienced a decline in operating revenue and gross profit due to the lack of renewal arrangements for certain businesses after their expiration [1]